Sickle cell warrior Victoria Gray, the first patient to enroll in the Casgevy gene editing trial, shared some highs and lows from her personal story and unveiled her first children's book. Gray was a ...

New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in children with SCN1A+ Dravet syndrome.

Throughout this three-part webinar series, experts from USP and industry will share first-hand experiences, case studies, and ...

Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24™ multiomics platform, Teton ...

The EvoLVcell stable producer cell line generation platform reportedly reduces variability and produces fewer impurities.

Built around the packages Sprint, Flex, and Flex+, Gene Synthesis 2.0 introduces a streamlined, intuitive ordering experience ...

Researchers mapped more than 100 mutations that allow diverse HIV-1 strains to evade broadly neutralizing antibodies.

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...

At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

There is no margin for error in the pharma and biopharma sectors. If the chain-identity breaks anywhere along the way, there ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

Macrophages use cell‑volume changes to sense danger, reprogram gene expression, and heighten inflammatory and antiviral ...